These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27582887)

  • 1. The role of naloxegol in the management of opioid-induced bowel dysfunction.
    Leppert W; Woron J
    Therap Adv Gastroenterol; 2016 Sep; 9(5):736-46. PubMed ID: 27582887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction.
    Leppert W
    Drug Des Devel Ther; 2015; 9():2215-31. PubMed ID: 25931815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction.
    Poulsen JL; Brock C; Olesen AE; Nilsson M; Drewes AM
    Clin Exp Gastroenterol; 2014; 7():345-58. PubMed ID: 25278772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
    De Giorgio R; Zucco FM; Chiarioni G; Mercadante S; Corazziari ES; Caraceni A; Odetti P; Giusti R; Marinangeli F; Pinto C
    Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
    Jones R; Prommer E; Backstedt D
    Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.
    Leppert W; Zajaczkowska R; Wordliczek J
    Expert Opin Pharmacother; 2019 Apr; 20(5):511-522. PubMed ID: 30625013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
    Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
    Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oral naloxegol vs subcutaneous methylnaltrexone in treatment of opioid-induced constipation in the hospital setting.
    Nero R; Allen B; Hailu K; Noor R; Theiss K
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S70-S76. PubMed ID: 36440903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxegol , a new drug for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of naloxegol in the treatment of opioid-induced constipation.
    Bruner HC; Atayee RS; Edmonds KP; Buckholz GT
    J Pain Res; 2015; 8():289-94. PubMed ID: 26109876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Profile of Naloxegol, a Peripherally Acting
    Floettmann E; Bui K; Sostek M; Payza K; Eldon M
    J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
    Anantharamu T; Sharma S; Gupta AK; Dahiya N; Singh Brashier DB; Sharma AK
    J Pharmacol Pharmacother; 2015; 6(3):188-92. PubMed ID: 26312011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
    Streicher JM; Bilsky EJ
    J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.
    Pergolizzi JV; Raffa RB; Pappagallo M; Fleischer C; Pergolizzi J; Zampogna G; Duval E; Hishmeh J; LeQuang JA; Taylor R
    Patient Prefer Adherence; 2017; 11():107-119. PubMed ID: 28176913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
    van Malderen K; Halawi H; Camilleri M
    Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities.
    Leppert W
    Contemp Oncol (Pozn); 2012; 16(2):125-31. PubMed ID: 23788866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.